259 related articles for article (PubMed ID: 12579999)
1. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.
Abraham RS; Katzmann JA; Clark RJ; Bradwell AR; Kyle RA; Gertz MA
Am J Clin Pathol; 2003 Feb; 119(2):274-8. PubMed ID: 12579999
[TBL] [Abstract][Full Text] [Related]
2. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.
Akar H; Seldin DC; Magnani B; O'Hara C; Berk JL; Schoonmaker C; Cabral H; Dember LM; Sanchorawala V; Connors LH; Falk RH; Skinner M
Amyloid; 2005 Dec; 12(4):210-5. PubMed ID: 16399645
[TBL] [Abstract][Full Text] [Related]
3. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect.
Shaheen SP; Levinson SS
Clin Chim Acta; 2009 Aug; 406(1-2):162-6. PubMed ID: 19410572
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of measurement of free light chains].
Matsuda M
Rinsho Byori; 2010 Apr; 58(4):401-4. PubMed ID: 20496770
[TBL] [Abstract][Full Text] [Related]
5. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.
Sanchorawala V; Seldin DC; Magnani B; Skinner M; Wright DG
Bone Marrow Transplant; 2005 Oct; 36(7):597-600. PubMed ID: 16044137
[TBL] [Abstract][Full Text] [Related]
6. Serum free light chains for monitoring multiple myeloma.
Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.
Bochtler T; Hegenbart U; Heiss C; Benner A; Cremer F; Volkmann M; Ludwig J; Perz JB; Ho AD; Goldschmidt H; Schonland SO
Haematologica; 2008 Mar; 93(3):459-62. PubMed ID: 18287137
[TBL] [Abstract][Full Text] [Related]
8. Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Martin W; Abraham R; Shanafelt T; Clark RJ; Bone N; Geyer SM; Katzmann JA; Bradwell A; Kay NE; Witzig TE
Transl Res; 2007 Apr; 149(4):231-5. PubMed ID: 17383597
[TBL] [Abstract][Full Text] [Related]
9. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
10. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.
Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088
[TBL] [Abstract][Full Text] [Related]
12. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
Katzmann JA; Clark RJ; Abraham RS; Bryant S; Lymp JF; Bradwell AR; Kyle RA
Clin Chem; 2002 Sep; 48(9):1437-44. PubMed ID: 12194920
[TBL] [Abstract][Full Text] [Related]
13. Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion.
Alyanakian MA; Abbas A; Delarue R; Arnulf B; Aucouturier P
Am J Hematol; 2004 Apr; 75(4):246-8. PubMed ID: 15054820
[TBL] [Abstract][Full Text] [Related]
14. [Clinical usefulness of serum free light chain measurement in monoclonal gammopathy].
Shimazaki C; Murakami H; Sawamura M; Matsuda M; Kinoshita T; Hata H; Sugiura I; Tsushita K; Nagura E; Kosugi H; Itoh J; Shimizu K
Rinsho Ketsueki; 2010 Apr; 51(4):245-52. PubMed ID: 20467220
[TBL] [Abstract][Full Text] [Related]
15. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
Lachmann HJ; Gallimore R; Gillmore JD; Carr-Smith HD; Bradwell AR; Pepys MB; Hawkins PN
Br J Haematol; 2003 Jul; 122(1):78-84. PubMed ID: 12823348
[TBL] [Abstract][Full Text] [Related]
16. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease.
Kaplan B; Ramirez-Alvarado M; Sikkink L; Golderman S; Dispenzieri A; Livneh A; Gallo G
Br J Haematol; 2009 Mar; 144(5):705-15. PubMed ID: 19076171
[TBL] [Abstract][Full Text] [Related]
17. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases.
Tate JR; Mollee P; Dimeski G; Carter AC; Gill D
Clin Chim Acta; 2007 Feb; 376(1-2):30-6. PubMed ID: 16945362
[TBL] [Abstract][Full Text] [Related]
18. The evolving use of serum free light chain assays in haematology.
Pratt G
Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
[TBL] [Abstract][Full Text] [Related]
19. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.
Nowrousian MR; Brandhorst D; Sammet C; Kellert M; Daniels R; Schuett P; Poser M; Mueller S; Ebeling P; Welt A; Bradwell AR; Buttkereit U; Opalka B; Flasshove M; Moritz T; Seeber S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8706-14. PubMed ID: 16361557
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder.
Vermeersch P; Van Hoovels L; Delforge M; Mariën G; Bossuyt X
Br J Haematol; 2008 Nov; 143(4):496-502. PubMed ID: 18729849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
